Read by QxMD icon Read


Leopoldo Spadea, Lucia Di Genova, Emanuele Tonti
PURPOSE: To use anterior segment optical coherence tomography (AS-OCT) to compare corneal stromal demarcation line depth after 4 treatment protocols of corneal crosslinking (CXL). SETTING: Eye Clinic, Sapienza University of Rome, Terracina (Latina), Italy. DESIGN: Prospective case series. METHODS: Patients with progressive keratoconus were delegated to one of the following CXL treatments: (1) conventional epithelium (epi)-off 3 mW/cm2 according to the standard Dresden protocol (C-CXL group), (2) accelerated epi-off 10 mW/cm2 (A-CXL group), (3) transepithelial epi-on 3 mW/cm2 (TE-CXL group), or (4) transepithelial epi-on by iontophoresis 10 mW/cm2 (I-CXL group)...
May 2018: Journal of Cataract and Refractive Surgery
Settimio Rossi, Carmine Santamaria, Rosa Boccia, Luigi De Rosa, Francesco Maria D'Alterio, Francesca Simonelli, Giuseppe De Rosa
BACKGROUND: To evaluate the clinical results of standard, transepithelial (TE) and iontophoresis (I) corneal cross-linking (CXL), in patients with progressive keratoconus. METHODS: Thirty eyes of 30 patients with progressive keratoconus treated by CXL (10 by standard-CXL, 10 by TE-CXL and 10 by I-TE-CXL) with 12 months of follow-up. Pre- and postoperative ophthalmologic testing were: uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), refractive examination (spherical error, spherical equivalent), corneal topography (corneal astigmatism, simulated maximum, minimum and average keratometry), aberrometry (coma and spherical aberration), pachymetry and endothelial cell density...
November 28, 2017: International Ophthalmology
Kanwal Latif, Muhammad Saeed Iqbal
OBJECTIVE: To assess the visual and topographical outcomes following accelerated trans-epithelial corneal crosslinking (TE-CXL) in progressive keratoconus. STUDY DESIGN: Case series. PLACE AND DURATION OF STUDY: Laser Vision Centre, Karachi, from January 2015 to December 2016. METHODOLOGY: Forty-five eyes of 25 patients affected with progressive keratoconus and treated with accelerated TE-CXL with riboflavin (vitamin B2) and ultra-violet A(UV-A) irradiation were enrolled in this study...
September 2017: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
Z R Lin, H P Wu, S R Luo, Z S Liu, N Dong, X M Shang, Z W Xie, L Yan, X Fang
Objective: To evaluate the clinical results of keratoconic eyes with a thin cornea treated with accelerated transepithelial corneal collagen cross-linking (A-TE-CXL) within 1 year. Methods: Nineteen eyes of 19 patients with progressive keratoconus with a minimum corneal thickness from 380 μm to 420 μm (including the epithelium) were included in this prospective, nonrandomized clinical study and treated with A-TE-CXL. Scoring of pain and foreign body sensation, slit lamp examination, uncorrected visual acuity, best corrected distance visual acuity, corneal topography, anterior segment optical coherence tomography, in vivo corneal confocal microscopy and endothelial cell count were assessed before surgery and at 1, 3, 6 and 12 months postoperatively...
September 11, 2017: [Zhonghua Yan Ke za Zhi] Chinese Journal of Ophthalmology
Bushra Akbar, Rana Intisar-Ul-Haq, Mazhar Ishaq, Sabahat Arzoo, Kashif Siddique
OBJECTIVE: The purpose of this study was to evaluate the safety and efficacy of transepithelial corneal collagen cross linking (TE-CXL) with modified riboflavin and accelerated UVA irradiance in thin corneas with pachymetry less than 400 microns at thinnest point, untreatable by epithelium off corneal collagen cross linking (CXL) in adult Pakistani population with progressive keratoconus. METHODS: This quasi experimental study included twenty six eyes of 26 patients with progressive keratoconus who underwent accelerated transepithelial CXL in Armed forced institute of ophthalmology with 12 months follow up...
May 2017: Pakistan Journal of Medical Sciences Quarterly
Mohamed A Heikal, Tarek Tawfik Soliman, Ayser Fayed, Abdelmonem M Hamed
PURPOSE: To evaluate the efficacy of transepithelial corneal collagen crosslinking (TE-CXL) in patients with progressive keratoconus. PATIENTS AND METHODS: This is a prospective interventional consecutive study carried out on 30 eyes of 18 patients with progressive keratoconus who underwent TE-CLX using both ParaCel™ (riboflavin 0.25%, hydroxy propyl methyl cellulose, NaCl, ethylenediaminetetraacetic acid [EDTA], Tris, and benzalkonium chloride) and vibeX-Xtra (riboflavin 0...
2017: Clinical Ophthalmology
Sameer Shahid Ameen, Mohammad Asim Mehboob, Kashif Ali
OBJECTIVE: To evaluate the efficacy and safety of transepithelial (TE) collagen cross-linking (CXL) in patients with progressive keratoconus (KC). METHODS: This Quasi Experimental Study was conducted at PNS Shifa Naval Hospital, Karachi from June 2015 to June 2016. Sixty eyes of 32 patients who underwent TE CXL for progressive KC from June 2015 to June 2016 were analysed to ascertain efficacy and safety of TE CXL procedure. Statistical analysis of the data was done using SPSS version 17...
September 2016: Pakistan Journal of Medical Sciences Quarterly
Hany S Elsaftawy, Mansour Hassan Ahmed, Mohamed Yasser Sayed Saif, Rasha Mousa
PURPOSE: To assess the clinical outcomes after sequential surgical implantation of intracorneal ring segments and transepithelial corneal collagen cross-linking (TE-CXL) in keratoconic eyes. METHODS: In this consecutive randomized study, 40 eyes of 29 patients with progressive mild to moderate keratoconus were included and were randomly divided into two groups. Group 1 included 20 eyes that underwent Keraring implantation, and group 2 included 20 eyes that underwent Keraring insertion followed by TE-CXL 1 month later...
November 2015: Cornea
Daniel M Gore, David O'Brart, Paul French, Chris Dunsby, Bruce D Allan
PURPOSE: To measure depth-specific riboflavin concentrations in corneal stroma using two-photon fluorescence microscopy and compare commercially available transepithelial corneal collagen cross-linking (CXL) protocols. METHODS: Transepithelial CXL riboflavin preparations--MedioCross TE, Ribocross TE, Paracel plus VibeX Xtra, and iontophoresis with Ricrolin+--were applied to the corneal surface of fresh postmortem rabbit eyes in accordance with manufacturers' recommendations for clinical use...
July 2015: Investigative Ophthalmology & Visual Science
Mengmeng Wang, Fengju Zhang, Xu Zhao, Yanzheng Song, Miao Zhang
PURPOSE: The aim of this study was to evaluate riboflavin in rabbit corneas before and after corneal collagen cross-linking (CXL) using confocal laser scanning microscopy. DESIGN: A randomized controlled experimental study. METHODS: The study was divided into 3 parts. In part 1 of this study, 30 eyes from 15 rabbits were used to evaluate riboflavin in de-epithelialized corneas before standard CXL. In part 2, 12 eyes from 6 rabbits were used to compare the differences of riboflavin concentration between standard CXL and transepithelial CXL (TE-CXL)...
November 2014: Asia-Pacific Journal of Ophthalmology
Igor Knezović, Mirna Belovari Višnjić, Hrvoje Raguž
Aim. To report a case of 40-year-old male with progressive bilateral keratoconus who had undergone transepithelial phototherapeutic keratectomy (TE-PTK) and corneal collagen cross-linking (CXL) using hypoosmolar riboflavin solution in a same day procedure. Methods. Eye examination showed that UCDVA on both eyes was 0,01 according to Snellen charts, and slit lamp biomicroscopy showed paracentral diffuse intrastromal corneal haze. Anterior OCT marked stromal hyperreflective zones and localized paracentral thinning of the cornea...
2015: Case Reports in Ophthalmological Medicine
S Rossi, A Orrico, C Santamaria, V Romano, L De Rosa, F Simonelli, G De Rosa
PURPOSE: Evaluating the clinical results of trans-epithelial collagen cross-linking (CXL) and standard CXL in patients with progressive keratoconus. METHODS: This prospective study comprised 20 eyes of 20 patients with progressive keratoconus. Ten eyes were treated by standard CXL and ten by trans-epithelial cross-linking (TE-CXL, epithelium on) with 1 year of follow-up. All patients underwent complete ophthalmologic testing that included pre- and postoperative uncorrected visual acuity, corrected visual acuity, spherical error, spherical equivalent, corneal astigmatism, simulated maximum, minimum, and average keratometry, coma and spherical aberration, optical pachymetry, and endothelial cell density...
2015: Clinical Ophthalmology
Nienke Soeters, Robert P L Wisse, Daniël A Godefrooij, Saskia M Imhof, Nayyirih G Tahzib
PURPOSE: To compare the clinical effects and safety of transepithelial corneal cross-linking (CXL) to epithelium-off (epi-off) CXL in progressive keratoconus. DESIGN: Randomized clinical trial (noninferiority). METHODS: Patients received either transepithelial CXL with Ricrolin TE (n = 35) or epi-off CXL with isotonic riboflavin (n = 26) in 1 academic treatment center, using a simple unrestricted randomization procedure. The main outcome measure was clinical stabilization of keratoconus after 1 year, defined as a maximal keratometry (Kmax) increase <1 diopter (D)...
May 2015: American Journal of Ophthalmology
Z Shalchi, X Wang, M A Nanavaty
This review aims to assess the efficacy and safety of epithelial removal (ER) and transepithelial (TE) corneal collagen crosslinking (CXL) for the treatment of keratoconus. We used MEDLINE to identify all ER and TE CXL studies on keratoconic eyes (n≥20, follow-up ≥12 months). Ex vivo and studies for non-keratoconus indications or in conjunction with other procedures were excluded. Data on uncorrected (UDVA) and corrected (CDVA) distance visual acuity, refractive cylinder, maximum keratometry (Kmax), and adverse events were collected at the latest follow-up and 1 year...
January 2015: Eye
Paolo Vinciguerra, Rita Mencucci, Vito Romano, Eberhard Spoerl, Fabrizio I Camesasca, Eleonora Favuzza, Claudio Azzolini, Rodolfo Mastropasqua, Riccardo Vinciguerra
PURPOSE: To compare biomechanical effect, riboflavin penetration and distribution in transepithelial corneal collagen cross-linking with iontophoresis (I-CXL), with standard cross linking (S-CXL) and current transepithelial protocol (TE-CXL). MATERIALS AND METHODS: The study was divided into two different sections, considering, respectively, rabbit and human cadaver corneas. In both sections corneas were divided according to imbibition protocols and irradiation power...
2014: BioMed Research International
Maddalena De Bernardo, Luigi Capasso, Antonia Tortori, Michele Lanza, Luisa Caliendo, Nicola Rosa
PURPOSE: To evaluate keratoconus biomechanical changes after transepithelial corneal collagen cross linking (TE CXL) using riboflavin and ultraviolet A (UVA). SETTING: Second University of Naples, Naples, Italy. DESIGN: Prospective non comparative case series study. METHODS: Patients with progressive keratoconus were examined, before and during a 6 months follow up after TE CXL, with a Pentacam, an Ocular Response Analyzer and an IOLMaster...
December 2014: Contact Lens & Anterior Eye: the Journal of the British Contact Lens Association
I Kocak, A Aydin, F Kaya, H Koc
PURPOSE: To evaluate the safety and efficacy of transepithelial corneal collagen crosslinking (TE-CXL) as compared to epithelium-off crosslinking (epi-off CXL) in progressive keratoconus. METHODS: Records of keratoconus patients treated with TE-CXL or epi-off CXL were reviewed retrospectively. Patients were included if they had at least 12months follow-up. Pre- and postoperative measurements of visual acuity, refractive errors, keratometry, corneal topography and pachymetry were assessed and compared...
May 2014: Journal Français D'ophtalmologie
Aldo Caporossi, Cosimo Mazzotta, Anna Lucia Paradiso, Stefano Baiocchi, Davide Marigliani, Tomaso Caporossi
PURPOSE: To assess the clinical results of transepithelial collagen crosslinking (CXL) in patients 26 years and younger with progressive keratoconus suitable for epithelium-off (epi-off) CXL. SETTING: Department of Ophthalmology, Siena University Hospital, Siena, Italy. DESIGN: Prospective case series. METHODS: The study included 26 eyes (26 patients) treated by transepithelial (epithelium-on) CXL. The mean age was 22 years (range 11 to 26 years) (10 younger than 18 years; 16 between 19 years and 26 years)...
August 2013: Journal of Cataract and Refractive Surgery
Adriano Magli, Raimondo Forte, Achille Tortori, Luigi Capasso, Giovanni Marsico, Elena Piozzi
PURPOSE: To compare efficiency and safety of epithelium-off corneal cross-linking (CXL) and transepithelial cross-linking (TE-CXL) in pediatric patients with progressive keratoconus. METHODS: Uncorrected and corrected visual acuity, corneal topography and pachymetry (Pentacam; Oculus Pentacam), and in vivo confocal microscopy (HRT II, Rostock Cornea Module, Heidelberg Engineering, Heidelberg, Germany) were evaluated at baseline and at 3, 6, and 12 months. RESULTS: In the epithelium-off CXL group (19 patients, 23 eyes; mean age, 14...
May 2013: Cornea
Massimo Filippello, Edoardo Stagni, Donato Buccoliero, Vincenza Bonfiglio, Teresio Avitabile
PURPOSE: To analyze the modifications of the corneal layers after transepithelial (TE) corneal cross-linking (CXL). METHODS: Twenty eyes of 20 patients with progressive keratoconus were treated with TE-CXL (without epithelium debridement), and their corneas analyzed at different times, up to 18 months, by confocal microscopy using a Nidek Confoscan 4. RESULTS: The epithelial layer, after an initial disorganization due to the TE technique, returned to a normal state after 2 weeks...
October 2012: Optometry and Vision Science: Official Publication of the American Academy of Optometry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"